EMEA-001974-PIP01-16-M02
Key facts
| Active substance |
Autologous CD34+ hematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human adenosine deaminase gene
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0400/2018
|
| PIP number |
EMEA-001974-PIP01-16-M02
|
| Pharmaceutical form(s) |
Dispersion for infusion
|
| Condition(s) / indication(s) |
Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
AdRes EU B.V.
Tel. +44 2033846700 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|